Skip to main content
CMXHF logo

CSL Limited (CMXHF) Stock: Price, Forecast & Analyst Target

CSL Limited (CMXHF) — price $128.26 (-6.23%), as of the Nov 19, 2026 trading session; market cap $61.6B.

Educational signal · not a buy or sell recommendation · How to read this

$128.26 −$8.52 (-6.23%) Market Cap $61.6B

CSL Limited · CMXHF · Healthcare · Biotechnology

CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RPRX · Royalty Pharma plc · 73 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100
  • GMAB · Genmab A/S · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$128.26
Change on the day-6.23%
52-week range$63.84–$141.83
Market capitalisation$61.6B—
Price / earnings (trailing)24.08
Shares traded on the day500
Beta (volatility vs the S&P 500)0.08

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $68, high $143, latest $128. $143 $68 high $143 Oct 17, 2025 Nov 19, 2026 · $128 $135Oct 17, 2025$121Oct 31, 2025$116Nov 14, 2025$117Nov 28, 2025$119Dec 12, 2025$118Dec 26, 2025$120Jan 9, 2026$120Jan 23, 2026$131Feb 6, 2026$105Feb 20, 2026$98Mar 6, 2026$98Mar 20, 2026$96Apr 2, 2026$97Apr 17, 2026$90May 1, 2026$71May 15, 2026$68May 29, 2026$74Jun 12, 2026$80Jun 26, 2026$86Jul 10, 2026$82Jul 24, 2026$92Aug 7, 2026$120Aug 21, 2026$127Sep 4, 2026$122Sep 18, 2026$128Oct 2, 2026$124Oct 16, 2026$135Oct 30, 2026$137Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for CSL (CMXHF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Moderate

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is CSL (CMXHF), and what does it report?

Short answer

CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. CSL Limited (CMXHF) is classified as Healthcare / Biotechnology. SEC filing business address: 45 Poplar RD, Prakville Victoria Austra, C3, 00000. It employs 29,000 people and is led by Gordon Naylor DipCompSc. In Q4 FY2026 it reported revenue of $7.30B and net income of -$2.93B. The market values it at $61.6B.

2 · Latest results

What do the latest results show for CSL (CMXHF)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of $7.30B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026$7.30B-$2.93B-$6.13 (diluted)
Q2 FY2026$8.44B$408M$0.84 (diluted)
Q4 FY2025$7.26B$1.03B$2.12 (diluted)
Q2 FY2025$8.21B$2.01B$4.13 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CSL (CMXHF)?

Short answer · as of

Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 3.94 · Piotroski F 5. Trailing ratios: ROE -15.8% · ROA 7.3% · current ratio 2.21.

Data-derived red flags

  • Negative return on equity (-15.8%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at CSL (CMXHF)?

Short answer · as of

Current published price targets run low $213.00 · high $213.00 · consensus $213.00 · median $213.00 against a quoted price of $128.26 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$213.00 – $213.00
Consensus target
$213.00
Median target
$213.00

Consensus record · Captured .

Measured against a quoted price of $128.26 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CMXHF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CMXHF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

CMXHF Healthcare Stock FAQ

These answers are editorial: 1 of these 8 answers is drawn from the CMXHF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is CMXHF a good stock to buy?

Stock Expert AI does not rate CMXHF buy, sell or hold. CSL Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CMXHF stock price today?

The last price recorded for CSL Limited (CMXHF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CMXHF price target?

The analyst consensus price target for CSL Limited (CMXHF), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for CMXHF?

The main risks for CMXHF include changes in regulatory requirements, competition from other biotechnology companies, economic downturns, and supply chain disruptions. These risks could negatively impact CSL's financial performance and stock price.

What are the key factors to evaluate for CMXHF?

Evaluate CMXHF on fundamentals, analyst consensus, and risk factors. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.

How frequently does CMXHF data refresh on this page?

CMXHF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CMXHF's recent stock price performance?

CSL Limited (CMXHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in plasma-derived therapies and influenza vaccines. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CMXHF overvalued or undervalued right now?

The trailing P/E of CSL Limited (CMXHF) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 28 figures on this page — 1 from SEC filings and earnings calls, 24 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.